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Michel S. Makaroun, MD, and Rabih A. Chaer, MD, Pittsburgh, Pa
Objective: Restenosis following tibial artery endovascular interventions (TAEIs) is thought to be benign but is not well
characterized. This study examines the consequences and predictors of recurrent stenosis of TAEIs for critical limb
ischemia.
Methods: All TAEIs for critical limb ischemia performed between 2004 and 2010 were retrospectively reviewed. Restenosis
was detected by noninvasive imaging and angiography when indicated. Restenoses were identiﬁed and the limb outcomes
recorded. Tibial reinterventions were performed only for persistent, worsening, or recurrent tissue loss or rest pain with
evidence of recurrence on duplex ultrasound or hemodynamic imaging. The c2 test and logistic regression were applied as
indicated. One-year patency rates were calculated using the Kaplan-Meier method.
Results: A total of 235 limbs in 210 patients were treated for critical limb ischemia (70% tissue loss, 30% rest pain).
Tissue loss included gangrene (49%) and ulcers (51%), and involved the forefoot (80%), the heel (14%), or both (6%).
Seventy-eightpercentof limbshadTrans-Atlantic InterSocietyConsensusC/Dlesions,withmeanpreoperative runoff score
of 12. Interventions were isolated tibial (45%) or multilevel (55%) (including tibial). Mean postoperative runoff score
improved to 6.6, but restenosis occurred in 96 limbs (41%) at amean of 4months. The 1-year primary patency was 59%with
amean follow-upof 9months.Restenosis presentedwith a persistentwound (32%),worsenedwound (42%), rest pain (16%),
or no symptoms (10%). A repeat TAEIwas performed in 42 (44%),major amputation in 26 (27%), open bypass in 20 (21%),
and observation in eight (8%). The overall amputation rate was 13%, but limb loss was signiﬁcantly higher in patients with
restenosis (n[ 26 [27%]) than in patients with no restenosis (n[ 5 [4%]; P < .001). Patients with restenosis and tissue loss
were more likely to have presented with gangrene (63% vs 38%; P [ .0003) but had comparable wound distribution
(P[NS). There was a trend toward a higher restenosis rate in patients with renal insufﬁciency (odds ratio, 5.57; P[ .08),
but this was unaffected by diabetes, statin therapy, or smoking (P [ NS). The rate of repeat intervention after the ﬁrst
reintervention was 36%, with an 87% overall limb salvage rate.
Conclusions: TAEIs can be used successfully to treat patients with critical limb ischemia with acceptable limb salvage rates.
Special attention should be given to patients with extensive tissue loss or gangrene because they are at risk for early
restenosis and subsequent limb loss. Strict wound and hemodynamic surveillance, wound care, and timely reinterventions
are crucial to achieve successful outcomes in this patient population. Amputation or alternative revascularization options,
when feasible, should be considered in patients with restenosis and tissue loss given the high rate of limb loss with tibial
reinterventions. (J Vasc Surg 2013;57:692-9.)Tibial artery endovascular interventions (TAEIs) have
become a ﬁrst line-approach of revascularization in many
centers in patients with tibioperoneal occlusive disease.1-5
Several studies have shown the efﬁcacy and procedural safety
of TAEI for the treatment of critical limb ischemia
(CLI).1,6-9 Low patency rates after endovascular interven-
tions, especially in infrapopliteal arteries, and high restenosis
rates have been uniformly noted, with a high rate of restenosisthe Division of Vascular Surgery, Department of Surgery, University
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and reinterventions have been traditionally considered to be
benign and successful, without signiﬁcant consequences on
limb outcomes.14 This perception may be based on the ease
of reinterventions, as lesions typically regress back to their
baseline angiographic presentationwithout any disease exten-
sion or loss of outﬂow vessels.6-8,12,13,15However, the impact
of tibial restenosis and reinterventions inpatientswithCLIhas
not beenwell characterized.This study sought to examine the
consequences and predictors of recurrent stenosis of TAEI in
the setting of CLI and its effect on wound healing and limb
salvage.
METHODS
Patient population. All patients who underwent
TAEI between September 2004 and May 2010 were
retrospectively identiﬁed from a prospectively maintained
registry, and patient characteristics, comorbidities, inter-
ventions, and complications were recorded. Patients were
treated for rest pain (Rutherford class 4) and/or tissue
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with acute ischemia were excluded from the study. Patients
who experienced restenosis and underwent reintervention
were identiﬁed. Clinical outcomes, including patency rates,
limb salvage, and wound healing, were determined. Each
preprocedural and postprocedural angiogram was reviewed
to assess baseline and postprocedural popliteal-tibial runoff
score. Except for our standard follow-up protocol, there
were no set revascularization protocols within our group
for patients presenting with CLI. Hence, treatment biases
were based on individual surgeon practices and as such
reﬂect real-world clinical practice.
Endovascular intervention and reinterventions. All
endovascular interventions were performed by vascular
surgeons with patients under local anesthesia and moderate
conscious sedation, using ﬁxed imaging in hybrid operating
rooms or interventional radiology suites. The majority of
the interventions (79%) were performed through contralat-
eral retrograde common femoral access, whereas ipsilateral
antegrade common femoral and left transbrachial access
was used selectively. Interventions were performed after
systemic heparinization (100 U/kg). During the index
procedure, interventions were performed with an intention
to establish in-line arterial ﬂow to the foot. At least one
tibial artery was revascularized, and additional tibial vessels
were treated based on the ease of the revascularization and
operator preference. During repeat endovascular interven-
tions, hemodynamically signiﬁcant recurrent stenosis at the
site of the initial lesion and any stenosis proximal or distal
to this lesion were intervened upon to re-establish in-line
ﬂow to the foot. More than 30% residual stenosis was
considered signiﬁcant angiographically.16 Tibial stenting
was generally avoided and was used only as a bailout to
treat ﬂow-limiting dissections or persistent occlusions.
Concomitant femoropopliteal occlusions were recanal-
ized and treated, primarily with angioplasty and selective
stenting. Pedal angioplasty was performed to improve
outﬂow in patients with tandem pedal lesions. All patients
were treated with an antiplatelet agent, either clopidogrel
or aspirin, unless there was a clear contraindication.
Follow-up protocol. All patients were followed clini-
cally with serial noninvasive arterial studies. In addition,
patients with tissue loss were followed in the outpatient
clinic on a weekly basis for wound care. Noninvasive
vascular laboratory surveillance was routinely performed
on all patients at 1 month, 3 months, and 6 months post-
procedure. Patients were then evaluated at 6-month
intervals. The travel distance was used as a surrogate
measure of the difﬁculty for patients to come back for
frequent weekly wound care visits.
Tibial restenosis. Restenosis was detected by noninva-
sive imaging and angiography as needed. Restenosis was
suspected based on noninvasive testing, which conﬁrmed
recurrent disease (ankle-brachial index decrease >0.15,
dampened pulse volume recordings, or evidence of
stenoses by duplex ultrasound scan), regardless of symptom
status. Although there are no standard duplex criteria for
classiﬁcation of tibial stenoses, we have utilized PSV>300 cm/s and peak stenotic velocity to prestenotic
velocity ratio of 3.5 as indicators of severe stenosis based
on our local surveillance protocol.17 Tibial restenosis was
also suspected on clinical grounds if there was lack of
improvement in wound healing 4 weeks after the TAEI,
increased tissue compromise compared with initial pre-
sentation, or need for major amputation. This was
conﬁrmed on repeat angiography only in patients with
recurrent symptoms or failure of wound healing. Wound
healing was used as an additional surrogate clinical sign for
restenosis. Patients with worsening wounds despite wound
care and with absence of local confounding factors, such
as infection or poor ofﬂoading, were reevaluated with
angiography even if noninvasive testing was inconclusive
for restenosis. Standard deﬁnitions of primary, primary-
assisted, and secondary patency rates were used as previ-
ously described.9
Classiﬁcation of disease distribution. The TransAt-
lantic Inter-Society Consensus document18 (TASC I)
tibial classiﬁcation was used to describe the distribution and
extent of occlusive disease, given that the TASC-II revision
did not include a tibial classiﬁcation. Popliteal and tibial
runoff scores were calculated according to a modiﬁcation of
the Society for Vascular Surgery criteria as published by
Davies et al.19 The TASC-II classiﬁcation was used to
classify femoropopliteal disease into A, B, C and D.20
Statistical analysis. All statistical analyses were
completed using SAS software (version 9.1; SAS Institute,
Cary, NC). Univariate descriptive statistics were assessed
for all patients’ sex, age, and comorbid conditions as well
as for key clinical measures described in the following
section. Limb wound types prompting TAEI were
compared for subsequent occurrence of restenosis using
the Fisher exact test. A logistic regression model was built
to identify patient characteristics explaining restenosis.
Preoperative and postoperative popliteal and tibial runoff
scores were compared in limbs that developed restenosis
vs those that did not develop restenosis using the Student
t-test. Limb loss in the restenosis and no restenosis groups
was compared using the c2 test. Patency and limb loss were
plotted using the Kaplan-Meier method.
RESULTS
A total of 235 limbs in 210 patients were treated with
TAEI for CLI. Demographic data and comorbidities of
patients undergoing TAEI are given in Table I. The indica-
tion for intervention included tissue loss in 165 limbs
(70%) and rest pain in 70 limbs (30%; Table II). Tissue
loss included gangrene (49%) and ulcers (51%), and
involved the forefoot (80%), the heel (14%), or both
(6%). Severe occlusive disease was present in the majority
of limbs as reﬂected by the distribution of TASC-I lesions
(Table III) and runoff scores (Table IV). Although the
majority of patients who underwent an endovascular inter-
vention were bypass candidates, several were not due to the
lack of an adequate conduit or poor surgical risk. Most of
the access was obtained in the femoral artery; in two
patients (0.01%) a left brachial artery access was obtained.
Table II. Indications for index TAEI in limbs
Indication All TAEI limbs TAEI with no restenosis TAEI with restenosis P value
Rest pain 70/235 (30%) 50/139 (36%) 20/96 (21%) .78
Tissue loss 165/235 (70%) 89/139 (64%) 76/96 (79%)
Nonhealing ulcer 84/165 (51%) 56/89 (63%) 28/76 (36.5%) NS
Gangrene 81/165 (49%) 33/89 (37%) 48/76 (63.5%) .0003
Tissue loss location .12
Forefoot 132/165 (80%) 72/89 (80%) 61/76 (80%)
Hindfoot 23/165 (14%) 14/89 (16%) 9/76 (11%)
Both 10/165 (6%) 4/89 (4%) 6/76 (8%)
NS, Not signiﬁcant; TAEI, tibial artery endovascular intervention.
Table I. Characteristics of patients undergoing TAEI
Characteristics All TAEI TAEI with no restenosis TAEI with restenosis P value
Male 126/210 (60.2%) 68/121 (56%) 58/89 (65%) .48
Age, years 73.3 74.0 72.9 .76
Diabetes 137/210 (65.5%) 74/121 (61%) 63/89 (71%) .32
Chronic renal failure 90/210 (43.1%) 45/121 (37%) 45/89 (50%) .43
Ends-stage renal disease/dialysis 41/210 (19.5%) 20/121 (17%) 21/89 (24%) .20
Hypertension 192/210 (92%) 109/121 (90%) 83/89 (94%) .85
Statin therapy 113/210 (54%) 52/121 (43%) 61/89 (62%) .33
Coronary artery bypass graft 50/210 (25%) 20/121 (17%) 30/89 (55%) .12
Coronary artery disease 132/210 (63%) 74/121 (61%) 58/89 (66%) .80
Chronic heart failure 63/210 (30%) 31/121 (26%) 32/89 (36%) .50
Angina 16/210 (8%) 4/121 (3%) 12/89 (13%) .77
Unstable angina 1/210 (0.4%) 0/121 (0%) 1/89 (1%) .32
Myocardial infarction 62/210 (29%) 31/121 (26%) 31/89 (35%) .35
Chronic obstructive pulmonary disease 40/210 (19%) 26/121 (21%) 14/89 (16%) .42
History of cancer 32/210 (15%) 21/121 (17%) 11/89 (13%) .66
History of tobacco 71/210 (34%) 30/121 (25%) 41/89 (46%) .42
TAEI, Tibial artery endovascular intervention.
Table III. TASC I classiﬁcation (extent of infrapopliteal disease)
Limbs undergoing TAEI
(N ¼ 235)
Limbs with no restenosis
(N ¼ 139)
Limbs with restenosis
(N ¼ 96)
P
value
TASC A 5/235 (2%) 5/139 (4%) 0/96 (0%) .99
TASC B 47/235 (20%) 31/139 (22%) 16/96 (17%) .99
TASC C 81/235 (34%) 46/139 (33%) 35/96 (36%) .99
TASC D 102/235 (44%) 57/139 (41%) 45/96 (47%) .99
TAEI, Tibial artery endovascular intervention; TASC, TransAtlantic Inter-Society Consensus.
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achieved in 228 limbs (97%) during the index TAEI proce-
dure; however, improvement in popliteal-tibial runoff score
after the intervention was present in only 200 limbs (85%).
Despite angiographic technical success with establishment
of in-line ﬂow to foot either directly or via peroneal artery
collaterals, 35 limbs (15%) did not have signiﬁcant
improvement in runoff score due to compromised pedal
runoff or persistent high-grade stenosis in the remaining
tibial runoff vessels.
Isolated tibial interventions were performed in 106
limbs (45%), and concurrent multilevel interventions
including tibial arteries were performed in 129 limbs
(55%). Multilevel interventions included the femoro-popliteal segment in 55 limbs (23.4%), the popliteal artery
only in 41 limbs (17.6%), the superﬁcial femoral artery only
in 24 limbs (10.4%), and a bypass graft intervention in
seven limbs (3.3%). Mean follow-up was 9 months (range,
1-36.9 months).
Tibial restenosis or reocclusion occurred in 96 limbs
(41%) of 89 patients (42%) at 1 year. Mean time for detec-
tion of restenosis was 5.8 months 6 2.8 months (range,
0.5-27 months). Fifty-four percent of the patients needed
to travel more than 35 miles for frequent wound care visits
and were followed locally; these patients were temporarily
lost to follow-up. The presentation of tibial restenosis
included a persistent wound in 30 limbs (32%); recurrent,
new, or worsened wound in 41 limbs (42%); rest pain in
Table IV. Modiﬁed Society for Vascular Surgery runoff scores
All TAEI limbs Limbs with no restenosis Limbs with restenosis P value
Preintervention runoff score 11.9 (5-19) 11.9 (6-19) 11.6 (5-19) .52
Postintervention runoff score 6.6 (1-17.5) 6.4 (1-9) 6.7 (1-17.5) .54
Runoff score improvement in index TAEI 5.3 5.5 4.9 .29
TAEI, Tibial artery endovascular intervention.
Table V. Logistic regression model to predict tibial
restenosis
Variable OR CI
P
value
Male 1.52 0.73-3.2 .27
Age 0.98 0.95-1.01 .19
Diabetes 0.89 0.40-1.97 .78
CRF/end-stage renal disease 5.57 0.01-1.25 .08
Hypertension 0.90 0.24-3.40 .88
Statins therapy 1.56 0.72-3.38 .26
Coronary artery bypass graft 1.12 0.45-2.83 .81
Coronary artery disease 0.99 0.38-2.62 .99
Chronic heart failure 1.34 0.56-3.19 .51
Angina 2.10 0.44-10.08 .35
Myocardial infarction 1.33 0.52-3.38 .55
Chronic obstructive pulmonary
disease
0.33 0.11-0.95 .04
Tobacco use 0.56 0.22-1.41 .22
Smoking 1.28 0.68-2.40 .44
Gangrene 3.12 1.23-6.78 .03
Ulcer 1.86 0.56-3.48 .09
Improvement in runoff score 1.19 0.10-14.01 .89
Postprocedural runoff score 0.88 0.63-1.22 .44
CI, Conﬁdence interval; CRF, chronic renal failure; OR, odds ratio.
Table VI. Management of limbs with tibial restenosis
Interventions No. (%)
Repeat TAEI 42/96 (44%)
Balloon angioplasty 37/42 (88%)
Laser atherectomy 4/42 (9.6%)
Thrombolysis 1/42 (2.4%)
Open surgical bypass 20/96 (21%)
Major amputation 26/96 (27%)
Clinical observation 8/96 (8%)
TAEI, Tibial artery endovascular intervention.
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tiﬁed on noninvasive surveillance imaging. Restenosis was
more common in patients undergoing TAEI for tissue
loss, especially in patients presenting with gangrene
(63.5% restenosis vs 37% no restenosis; P ¼ .0003). The
rate of restenosis in patients with ulcers only was not statis-
tically signiﬁcant (36.5% restenosis vs 62.5% no restenosis;
P ¼ .157).
Both groups were comparable in age, gender, and
comorbidities (Tables I and V). There was a trend toward
higher restenosis rates in patients with renal insufﬁciency21
(odds ratio [OR], 5.57; P ¼ .08), but this was unaffected
by diabetes, statin therapy, or smoking (P ¼ NS). Similarly,
the degree of improvement from preoperative runoff score
to postoperative runoff score and the postoperative runoff
score itself did not predict restenosis. However, gangrene
as an indication for intervention was predictive of restenosis
(OR, 3.12; P ¼ .03). A similar trend was seen in ischemic
ulcers but was not statistically signiﬁcant (OR, 1.86; P ¼ .9;
Table V).
A secondary intervention was performed in 42 of 96
limbs (44%) with restenosis (Table VI). Balloon angioplasty
was the most common modality used for reintervention
(37/42 limbs [88%]). Adjunctive interventions includedlaser atherectomy (4/42 limbs [9.6%]) and thrombolysis
(1/42 limbs [2.4%]). A major amputation was required
in 26 of the 96 limbs (27%) that developed restenosis for
a variety of reasons, which precluded limb salvage
(Table VII), including poor surgical risk, lack of a target
vessel, or nonsalvageable extremity with extensive tissue
loss. Conversion to open surgical bypass was performed
in 20 of the 96 limbs (21%) with restenosis, and clinical
observation was performed in eight of 96 limbs (8%) in
asymptomatic patients.
Additional episodes of restenosis were detected in 15 of
42 limbs (36%), which underwent a second reintervention.
Of these 15 limbs that underwent re-reintervention, ﬁve
(33%) required major amputation and three (20%) required
a subsequent reintervention. Mean number of reinterven-
tions was three (range, two to ﬁve interventions).
Patency rates at 1 year postintervention were estimated
using Kaplan-Meier curves. The primary patency rate was
59% (136/235 limbs), the primary-assisted patency rate
was 70% (165/235), and the secondary patency rate was
76% (179/235) at 1 year (Fig). The limb salvage rate at
1 year was 87% (204/235 limbs). The overall amputation
rate was 13% (31/235 limbs), but limb loss was signiﬁ-
cantly higher in patients with recurrent stenosis (27%
[26/97 limbs]) compared with patients who maintained
primary patency (n ¼ 5 [4%]; P <.001). Six patients (6/
26 [23%]) who sustained limb loss were candidates for
bypass but did not undergo close follow-up and progressed
to an unsalvageable limb. Others were not candidates
either because of lack of conduit or poor surgical risk.
Table VII lists the clinical characteristics of the patients
with the 26 limbs (27%) that underwent major amputation
after developing restenosis following TAEI. A mean of
three TAEIs were performed prior to major amputation
in these 26 limbs. The majority of amputations were
performed in patients who were deemed to have
Table VII. Characteristics of patients undergoing major amputation after TAEI (N ¼ 26) compared with all the patients
(N ¼ 210)
Characteristics No. (%) (N ¼ 26) No. (%) (N ¼ 210)
Age, years
<59 2/26 (8%) 21/210 (10%)
60-69 8/26 (31%) 37/210 (18%)
70-79 11/26 (42%) 61/210 (29%)
>80 5/26 (19%) 83/210 (40%)
Mean 72.2 years 73.3 years
Cardiopulmonary risk
Mild 3/26 (12%)
Moderate 13/26 (50%)
High 10/26 (38%)
Renal status
Normal 15/26 (58%) 169/210 (80%)
End-stage renal disease 11/26 (42%) 41/210 (20%)
Functional status
Ambulatory 14/26 (54%)
Limited ambulation 7/26 (27%)
Nonambulatory 5/26 (19%)
Adequate vein conduit
Available 6/26 (23%)
Not available 20/26 (77%)
Extent of wound
Salvageable 8/26 (31%)
Nonsalvageable 18/26 (69%)
Bypass target vessel
No target 9/26 (35%)
Target present 17/26 (65%)
Previous coronary artery bypass graft 7/26 (27%) 50/210 (24%)
Previous open revascularization
Ipsilateral limb 11/26 (42%)
Contralateral limb 5/26 (19%)
No. of TAEIs prior to major amputation
Range 2-5 NA
Mean 3
Time interval between TAEI and major amputation
Range 7-332 days NA
Distance traveled for follow-up clinic visit, miles
Range 5-65
Mean 22.5
>35 miles of travel 14/26 (54%)
NA, Not applicable; TAEI, tibial artery endovascular intervention.
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ischemic ulcers (18/26 [69%]). Although 17 of 26 limbs
(65%) had a possible target vessel for bypass, the presence
of severe infection of extensive gangrene led to major
amputation. In 77% of limbs (20/26), the patient had no
suitable vein for bypass conduit (including arm vein). The
absence of vein conduits was secondary to a surgical harvest
for multiple redo ipsilateral bypass before TAEI (11/26
patients) or for contralateral bypass (5/26 patients), arte-
riovenous ﬁstula in patients with end-stage renal disease,
presence of varicose veins, or sclerotic/atretic veins. Ten
of the 26 patients (38%) undergoing major amputation
had high or prohibitive cardiopulmonary operative risk.
These major amputations were done under peripheral
nerve block and required much less operative time. As
such, they were believed to be better tolerated by patients
with cardiac or pulmonary risk. The majority of patients
(54%) were ambulatory at the time of amputation, 27%had limited ambulation, and 19% (n ¼ 26) were nonambu-
latory. The amputation was performed between 7 and 332
days after TAEI. Patients had to travel between 5 and 65
miles (mean, 22.3 miles) for follow-up visits, and 14 of
26 patients (54%) had to travel more than 35 miles for
follow-up visits. These patients mostly had frequent
home visits by the wound care team and sparse clinic visits.
DISCUSSION
Restenosis after a tibial artery intervention has long
been a criticism of this procedure. However, even with
the high reported rates of restenosis approaching 50% to
60% at 1 year,1 the clinical end points of limb salvage and
patient survival continue to be comparable to those of
open surgical revascularization.1,22,23 Therefore, tibial
vessel restenosis traditionally has been dismissed as clini-
cally benign, especially because reinterventions may not
be required after resolution of critical limb ischemia.
Fig. Patency in limbs undergoing tibial artery endovascular
interventions (TAEIs).
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infrapopliteal angioplasty and open bypass showing accept-
able limb salvage rates after intervention in patients with
CLI,1,4,13,16,24-26 no studies have focused on the repercus-
sions of tibial restenosis, particularly in patients with exten-
sive tissue loss or gangrene.
The current study demonstrates that TAEIs have
a high rate of restenosis, which is in line with the published
literature. However, our data suggest that these recurrent
lesions do not seem to follow a benign clinical course.
The present report demonstrates that patients with reste-
nosis had a high rate of major amputation during follow-
up despite initial technical success with tibial intervention.
Several factors precluded limb salvage, including a prohibi-
tive operative risk, absence of target vessel for surgical
revascularization, nonfunctional status, or extensive wound
progression that made further attempts at revascularization
futile. It can be argued that these patients represent
a selected group because aggressive endovascular interven-
tions are offered to patients who traditionally may only be
offered primary amputation. However, our study under-
lines the fact that patients who present with reversible
tissue loss have no margin for error, and that tibial resteno-
sis can result in progression of tissue loss beyond salvage
The low limb salvage rates in this group of patients under-
line the need for close clinical and hemodynamic surveil-
lance after TAEI. The presence of tissue loss, especially
gangrene, was noted to be more common in patients
who developed tibial artery restenosis and is a well-
known risk factor for limb loss. Frequent, often weekly,
wound care is crucial in patients with gangrene or extensive
tissue loss treated with TAEI to detect early clinical signs of
restenosis and initiate early revascularization as indicated, as
previously reported by our group on the outcomes of
wound healing after TAEI in patients with tissue loss.9
In our study, tibial restenosis was identiﬁed in 41% of
the treated limbs despite adequate procedural technicalsuccess, hemodynamic improvement, and patency docu-
mented on the ﬁrst postprocedure ultrasound surveillance.
Most recurrences appeared early in the postprocedural
period, with a mean time for detection of restenosis of 5
months. The early time frame to recurrence is critical in
patients with tissue loss, as we previously reported
a mean time to wound healing of 10.7 6 7.4 months after
TAEI for CLI.9 Such patients are unlikely to have healed in
such a short time frame and are at risk for early CLI
progression to gangrene and subsequent limb loss. In
a recent review of 13,258 Medicare patients across the
United States (90% with tissue loss), an even higher major
amputation rate (23.8%) was noted.3 This is comparable to
the amputation rate in our series of patients who developed
restenosis (27% vs 4%). Also, several patients who eventu-
ally had limb loss were noted to have a signiﬁcant travel
time for follow-up, which might explain the less intensive
surveillance. This ﬁnding suggests that patients with Ruth-
erford classes 5 and 6 CLI may be better served with
a more durable revascularization strategy with surgical
bypass if they cannot adhere to a strict rigorous weekly clin-
ical follow-up and structured surveillance. It is difﬁcult to
make comparative analysis between early open revasculari-
zation and TAEI based on this study because it was not
designed to evaluate this question. However, it can be
argued that a bypass with a vein or a prosthetic conduit
may result in better limb salvage if performed early when
the tissue loss is less extensive.12,27,28
The ﬁndings from the present study suggest that there
is cohort of patients with tibial restenosis in which reinter-
ventions may not be helpful and, in fact, may result in delay
in open revascularization with resulting limb loss. As such,
identifying such risk factors will be helpful in developing
a patient-speciﬁc strategy for limb salvage.
It is interesting to note that gangrene as an indication for
treatment was a predictor of restenosis following TAEI. It is
thought that an increased proinﬂammatory state in patients
with gangrene and foot sepsis might contribute to higher
rates of early restenosis in the group of patients with exten-
sive tissue necrosis or gangrene.29 This again underscores
the importance of a durable revascularization strategy in
this patient population, which seems to be at increased risk
for early failure with TAEI and possible progression of
CLI. Patients with tissue loss and no surgical bypass options
who undergo tibial reinterventions represent a particularly
challenging subset because limb salvage is limited. Given
the poor limb salvage rate, patients in that category with
restenosis and extensive tissue loss perhaps should be offered
an amputation as opposed to multiple reinterventions. The
majority of patients in our series who presented with
gangrene had a distal revascularization target, although
most did not have an optimal conduit.
In this study, the burden of tibial and popliteal disease
was calculated using the modiﬁed Society for Vascular
Surgery runoff score system validated by Davies et al19
given the lack of a tibial classiﬁcation in the current
TASC-II guidelines. We demonstrated a signiﬁcant im-
provement in postprocedural runoff scores after
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and the need for reintervention or eventual major amputa-
tion was not predictable based on the pre- or postinterven-
tion runoff score. It was also noted that although there was
a similar TASC lesion distribution, the presentation was
different with more gangrene in the restenosis group.
The exact reason for the differences in presentation cannot
be determined but can be postulated to be due to varia-
tions in the timing in seeking medical care and in the
quality of runoff.
Forty-four percent of patients with restenosis under-
went a repeat endovascular intervention, and 21% required
an open surgical bypass. Among patients who underwent
repeat endovascular intervention, the subsequent need for
repeat intervention was high. The persistence with endo-
vascular intervention was due to a combination of the
patients’ anatomic situation (target vessel or conduit limita-
tions) and overall medical condition, and resulted in poor
limb salvage rates. However, the reinterventions did appear
to delay the time to limb loss, with a mean time to major
amputation of 1 to 2 months from initial intervention.
Despite an acceptable overall limb salvage rate of 87% at
1 year, which is similar to published data,23 special consid-
eration should be given to patients with gangrene or exten-
sive tissue loss, who represented the majority of patients
(70% [165/235]) in this series. Limb salvage in this
subgroup is contingent on the understanding that the rates
of restenosis and reinterventions are high with TAEI, and
that the clinical course may not be benign and requires
close rigorous follow-up.
The ﬁndings from the present study suggest that there
is a cohort of patients with tibial restenosis for whom rein-
terventions may not be helpful and, in fact, may result in
delay in open revascularization with resulting limb loss.
Patients with gangrene had higher rates of restenosis and
major amputation. Although such patients may be success-
fully treated with TAEI, early implementation of open
surgical revascularization should be considered for those
patients with tissue loss, in general, and gangrene, in partic-
ular, if they present with early restenosis or if they cannot
adhere to a strict follow-up schedule. However, because
this study is a nonrandomized retrospective study, whether
an open revascularization would have outcomes better than
the TAEI is unknown.
There are several limitations to this study. The retro-
spective design is likely to introduce a selection bias given
the heterogeneous patient population treated by multiple
surgeons who may be biased toward different revasculariza-
tion techniques and devices. In addition, there are no
consensus guidelines to classify tibial interventions, and
different distributions of tissue loss and rest pain, which
may lead to mixed results when comparing outcomes,
may have resulted in misdiagnosis or delayed diagnosis of
restenosis. Additionally, our study lacks comparative anal-
ysis among open revascularization, TAEI, and conservative
therapy alone. Finally, the lack of validated duplex diag-
nostic criteria may have resulted in misdiagnosis or delayed
diagnosis of restenosis.Despite its limitations, the present study contributes to
a patient-speciﬁc CLI treatment strategy. Until more
durable results can be achieved with TAEI, perhaps with
drug-eluting balloons and drug-eluting and/or bio-
absorbable stents,30 patients with extensive tissue loss or
gangrene will need dedicated rigorous surveillance or alter-
native revascularization strategies when feasible. Stenting
for tibial lesions has not been uniformly associated with
favorable results, and drug-eluting balloons or stents are
currently not available in the United States for this applica-
tion but may provide a good option for patients with reste-
nosis. In addition, when TAEIs are used for limb salvage in
patients with no bypass options, a clear understanding of
their limitation is crucial to setting realistic expectations
for both the physician and the patient. Prior to embarking
on an all-endovascular ﬁrst policy, the results of this study
should serve as an impetus for better treatment algorithms
in patients with CLI and tissue loss in order to attain the
best rates of limb salvage and wound healing.
CONCLUSIONS
TAEIs can be successfully used to treat patients with
CLI, with acceptable limb salvage rates. Special attention
should be given to patients with extensive tissue loss or
gangrene because they are at risk for early restenosis and
subsequent limb loss. Strict wound and hemodynamic
surveillance, wound care, and timely reinterventions are
crucial to achieve successful outcomes in this patient popu-
lation. Amputation or alternative revascularization options,
when feasible, should be considered in patients with reste-
nosis and tissue loss given the high rate of limb loss with
tibial reinterventions.
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